BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30454003)

  • 1. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
    Wang H; Luo Y; Qiao T; Wu Z; Huang Z
    J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.
    Liu L; Fan J; Ai G; Liu J; Luo N; Li C; Cheng Z
    Biol Res; 2019 Jul; 52(1):37. PubMed ID: 31319879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitory effect of a Chinese medicine Xiaoaiping combined with cisplatin on the proliferation, invasion and apoptosis in ovarian cancer HO-8910 PM cells in vitro and in vivo].
    Zheng A; Li T; Chen Y; Fang J; Zhang Y; Feng J
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):11-6. PubMed ID: 26796800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy.
    Liu Q; Zhu D; Hao B; Zhang Z; Tian Y
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):17-22. PubMed ID: 29808795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
    Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
    Qi C; Zhang QH; Li JX
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
    Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
    Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells.
    Zhao WJ; Deng BY; Wang XM; Miao Y; Wang JN
    Asian Pac J Cancer Prev; 2015; 16(6):2453-8. PubMed ID: 25824780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
    Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
    Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
    Wang M; Ma X; Wang J; Wang L; Wang Y
    Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
    Hou L; Hou X; Wang L; Li Z; Xin B; Chen J; Gao X; Mu H
    Cancer Biomark; 2017 Dec; 21(1):187-194. PubMed ID: 29103028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression.
    Sun LM; Liu YC; Li W; Liu S; Liu HX; Li LW; Ma R
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1198-1205. PubMed ID: 28387913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.